Trial Profile

A Pilot Study of the Immunomodulatory Agent Acarbose in Combination with Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acarbose (Primary) ; Axitinib (Primary) ; Cabozantinib (Primary) ; Everolimus (Primary) ; Ipilimumab (Primary) ; Lenvatinib (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
Indications Renal cell carcinoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

21 Feb 2025 Planned End Date changed from 6 Oct 2025 to 1 Dec 2026.
21 Feb 2025 Planned primary completion date changed from 6 Oct 2025 to 1 Oct 2026.
21 Feb 2025 Planned initiation date changed from 5 Oct 2025 to 31 Dec 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com